Full Text
PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia

Abstract

Authors

A.V. Tikhomirova R.I. Yagudina A.U. Kulikov

Back to Volume 14, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×